FDA approves daraxonrasib pill to treat metastatic pancreatic cancer FAST-MOVING

pancreatic cancer FDA approval daraxonrasib Revolution Medicines oncology

The U.S. Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-its-kind pill for treating metastatic pancreatic cancer. Produced by Revolution Medicines and marketed under the brand name Rasonque, the daily medication targets a mutated protein that drives tumor growth in more than 90% of pancreatic cancer cases.

In a clinical study involving 500 patients whose cancer had stopped responding to previous treatments, those taking daraxonrasib showed a median survival of 13.2 months. This is a significant increase compared to the 6.7-month median survival observed in patients receiving standard chemotherapy. The drug was approved more than six months ahead of its target date.

While not a definitive cure, medical experts describe it as a vital new option for patients facing one of the deadliest forms of cancer. The American Cancer Society estimates that approximately 67,000 new cases will be diagnosed in the United States this year.

Entities

American Cancer Society · Food and Drug Administration · Rasonque · Revolution Medicines · daraxonrasib

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Patients treated with daraxonrasib had a median survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. vinnews.com · chicago.suntimes.com · wtop.com
[● 3 SOURCES] The American Cancer Society estimates 67,000 new pancreatic cancer cases will be diagnosed in the U.S. this year. vinnews.com · chicago.suntimes.com · wtop.com
[● 3 SOURCES] The FDA granted expedited approval to the pancreatic cancer drug daraxonrasib. vinnews.com · chicago.suntimes.com · wtop.com
[● 3 SOURCES] The FDA approved the drug more than six months ahead of its target date. vinnews.com · chicago.suntimes.com · wtop.com
[● 3 SOURCES] The drug blocks a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases. vinnews.com · chicago.suntimes.com · wtop.com
[● 3 SOURCES] Revolution Medicines will market the drug under the brand name Rasonque. www.mediapress24.it · vinnews.com · wtop.com